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Dear Editors,
In a recent issue of the American Journal of Cardiovas-
cular Drugs, Thomas et al. [1] analyzed the cardiovascular
safety of cyclo-oxygenase (COX)-2 inhibitors (coxibs). In
the Recommendations section of the paper, the authors
stated that, based on the results of the PRECISION
(Prospective Randomized Evaluation of Celecoxib Inte-
grated Safety versus Ibuprofen Or Naproxen) trial [2],
celecoxib at moderate doses is not inferior to ibuprofen or
naproxen in terms of cardiovascular safety. The PRECI-
SION investigators seem to imply that celecoxib is a
‘cardiovascular safe’ drug, and we would like to challenge
this statement with a more detailed analysis of the PRE-
CISION trial.
On the recommendation of the US FDA after the doubts
raised over the cardiovascular safety of the coxibs, Pfizer
performed the PRECISION trial [2], proposing as its pri-
mary objective ‘‘To assess the effects of celecoxib
100–200 mg twice daily (bid) and ibuprofen 600–800 mg
three times daily (tid) compared with naproxen
375–500 mg bid on the first occurrence of Anti-Platelet
Trialists Collaboration (APTC) composite cardiovascular
endpoint [cardiovascular death, including hemorrhagic
death, non-fatal myocardial infarction (MI), non-fatal
stroke] in subjects with osteoarthritis or rheumatoid
arthritis (RA), and pre-existing cardiovascular disease
(CVD) or at high risk for developing CVD. Cardiovascular
effects of celecoxib 100–200 mg bid will also be compared
with ibuprofen 600–800 mg three times daily’’ [3].
According to the authors’ conclusion, ‘‘at moderate doses,
celecoxib was found to be noninferior to ibuprofen or
naproxen with regard to cardiovascular safety’’, implying
that their results validate the safe use of celecoxib at the
same level as naproxen or ibuprofen.
The PRECISION investigators concluded that their trial
confirmed the primary hypothesis of non-inferiority [3].
However, we consider that the possibility of several biases
in the design and development of the trial do not allow its
results to be considered a reliable answer to the research
question of the trial.
Coxibs would find a place in therapeutics if they showed
equal anti-inflammatory and analgesic efficacy and fewer
gastrointestinal adverse effects without increasing cardio-
vascular harm compared with naproxen. Let us examine
each of these aspects in the PRECISION trial.
1 Anti-Inflammatory and Analgesic Efficacy:
Were Comparable Doses Used?
The therapeutic effects and adverse event profile of tradi-
tional non-steroidal anti-inflammatory drugs (NSAIDs) and
coxibs are dose dependent. For this reason, the comparison
of adverse events between pharmacologic agents is only
interpretable if therapeutically equivalent doses are used.
The PRECISION trial investigated celecoxib 200–400
mg/day compared with naproxen 750–1000 mg/day and
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ibuprofen 1800–2400 mg/day in patients with osteoarthritis
or RA. Patients started treatment with the lowest dose and
increased it as needed.
Since 200 mg/day is the maximum approved dose of
celecoxib for osteoarthritis in several countries, including
the USA [2], more than 90% of the population studied did
not exceed that dose. As a result, the average dose of
celecoxib (209 mg/day) used was practically equal to the
minimum dose, whereas those of naproxen (852 mg/day)
and ibuprofen (2045 mg/day) showed that a great number
of patients used the higher dose. This difference was
reflected in a lower analgesic effect with celecoxib than
with naproxen [2] and in a slightly higher percentage of
treatment discontinuation due to insufficient clinical
response among those completing the protocol [764/5853
for celecoxib (13.1%) versus 661/5849 for naproxen
(11.3%)] [4].
In conclusion, it is possible that the anti-inflammatory
and analgesic doses used were not equivalent, which
complicates the interpretation of adverse event rates.
2 Cardiovascular Adverse Events
In the PRECISION trial, 45% of patients were using aspirin
up to 325 mg/day because they had previous CVD or were
at high cardiovascular risk. The published report does not
clarify further use of this drug. Considering that COX-1 is
irreversibly inhibited by aspirin, this effect cancels the
COX-2 selectivity of celecoxib, which is suspected of
increasing cardiovascular risk, biasing the outcome toward
an absence of difference between both groups.
The initial protocol established that the upper limit of
the 95% confidence interval (CI) of one tail for the hazard
ratio of the primary outcome in the intention-to-treat (ITT)
analysis comparing celecoxib and ibuprofen versus
naproxen should not exceed 1.33. For the on-treatment
analysis (in which follow-up ended 30 days after the final
suspension of the drug under study), the initial margin was
set at 1.33 but then changed to 1.40 since the rate of car-
diovascular events was lower than expected [3].
However, a 33 or 40% increase in cardiovascular events
is not clinically irrelevant. Many well established cardio-
vascular risk factors produce effects of this magnitude and,
conversely, the benefits of statins, antihypertensives, or
antiplatelet agents are approximately in this order. In fact,
the cardiovascular risk of celecoxib (at a typical dose of
400 mg/day) compared with placebo is estimated at a rel-
ative risk of 1.36 (95% CI 1.0–1.84; p = 0.05) in the most
comprehensive meta-analysis available [5], an effect size
that coincides with the chosen Delta and that, therefore,
would be considered ‘acceptable damage’ from the trial
design itself.
In the PRECISION trial, 68.8% of patients stopped
taking the study drug, continuing their own anti-inflam-
matory treatment outside the protocol, which biases the
results towards an absence of difference between the
groups studied and thus favors a spurious verdict of ‘non-
inferiority’ [2].
If withdrawal from treatment biases the results toward
absence of difference, the high loss of follow-up (27.4%)
may produce further biases in either direction. The
observed primary outcome rates for the celecoxib,
naproxen, and ibuprofen groups were 2.3, 2.5, and 2.7%,
respectively, in the ITT analysis and 1.7, 1.8, and 1.9%,
respectively, in the on-treatment analysis. These minimal
differences between groups that support the conclusion of
non-inferiority of celecoxib could be substantially modi-
fied in either direction. In other words, for each patient
who experienced a cardiovascular event in the trial
(2.5%), more than ten patients were lost at follow-up
(27.4%). Therefore, the final results—if they could be
known—may clearly tip the balance in one direction or
another.
Given these biases, the PRECISION results cannot be
taken as evidence of non-inferiority of cardiovascular risk
between celecoxib and ibuprofen or naproxen.
3 Gastrointestinal Adverse Events: Late Changes
in Endpoints During Trial Implementation
Although gastrointestinal adverse events are clinically
relevant, they were not chosen as primary endpoints. It
should be noted that, by specification of the protocol, all
patients received esomeprazole during the trial [3], which
may bias the results of the trial and mask serious adverse
events.
The published trial protocol, in its final version dated
July 2016, defined one primary outcome, five secondary
outcomes, and ten tertiary outcomes in addition to other
‘exploratory analysis’ of variables. The gastrointestinal
secondary outcome measures the incidence of ‘‘clinically
significant gastrointestinal events’’ (CSGE), defined as the
first occurrence of either gastroduodenal hemorrhage;
gastric outlet obstruction; gastroduodenal, small bowel, or
large bowel perforation; large bowel hemorrhage; small
bowel hemorrhage; acute gastrointestinal hemorrhage of
unknown origin, including presumed small bowel hemor-
rhage or symptomatic gastric or duodenal ulcer. Tertiary
outcomes were the composite result of symptomatic high
gastrointestinal ulceration, moderate to severe abdominal
symptoms and withdrawal from the trial due to gastroin-
testinal adverse events, and first occurrence of clinically
significant gastrointestinal iron deficiency anemia
(CSGIDA) [3].
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In the trial, no statistically significant differences were
found between the three drugs in the secondary CSGE
outcome; however, in the tertiary CSGIDA outcome,
celecoxib had fewer events than naproxen or ibuprofen.
The published trial report presented a ‘‘composite out-
come of serious gastrointestinal events’’ as the main
gastrointestinal result, adding CSGE and CSGIDA, and
found the combination results significantly lower in the
celecoxib group than in the naproxen or ibuprofen groups
[2].
This new composite variable was not previously
informed. A letter signed by the chief statistician of the
trial confirmed that the decision to add CSGIDA to the
CSGE outcome was made before the unblinding of the trial
results but does not mention the reasons for the change [3].
It would have been preferable to stick to the published
statistical analysis plan.
4 Conclusion
Given the problems identified in the design, development,
and implementation of the PRECISION trial, we consider
that the cardiovascular non-inferiority status of celecoxib
compared with naproxen, as stated by Thomas et al. [1], is
questionable because of several biases that reduce the
possible differences between drugs studied in that trial.
Therefore, celecoxib should not be considered a
‘cardiovascular safe’ medicine when compared with other
treatments such as ibuprofen or naproxen.
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